Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna M Friedhuber

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
The Journal of Pharmacy and Pharmacology|December 11, 2012
Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine modelMei Lin Tan, Anna M Friedhuber, Crispin R Dass
The Journal of Pharmacy and Pharmacology|September 12, 2014
Nucleotropic doxorubicin nanoparticles decrease cancer cell viability, destroy mitochondria, induce autophagy and enhance tumour necrosisAnna M Friedhuber, Vijay Chandolu, Somkamon Manchun, et al.
Journal of Microencapsulation|May 10, 2008
Biocompatible chitosan-DNAzyme nanoparticle exhibits enhanced biological activityCrispin R Dass, Anna M Friedhuber, Levon M Khachigian, et al.
Cancer Biology & Therapy|April 17, 2008
Downregulation of c-jun results in apoptosis-mediated anti-osteosarcoma activity in an orthotopic modelCrispin R Dass, Anna M Friedhuber, Levon M Khachigian, et al.
Biomaterials|October 20, 2009
The performance of doxorubicin encapsulated in chitosan-dextran sulphate microparticles in an osteosarcoma modelMei L Tan, Anna M Friedhuber, Dave E Dunstan, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 19, 2010
A nanoparticulate system that enhances the efficacy of the tumoricide Dz13 when administered proximal to the lesion siteMei Lin Tan, Dave E Dunstan, Anna M Friedhuber, et al.
The Journal of Pharmacy and Pharmacology|September 12, 2014
Cardiomyocyte apoptosis vs autophagy with prolonged doxorubicin treatment: comparison with osteosarcoma cellsOktay Tacar, Sivanjah Indumathy, Mei Lin Tan, et al.
Bone|April 28, 2019
Triple-threat activity of PEDF in bone tumors: Tumor inhibition, tissue preservation and cardioprotection against doxorubicinYongzhong Wei, Mina Elahy, Anna M Friedhuber, et al.
Biomaterials|June 21, 2014
The potential role of free chitosan in bone trauma and bone cancer managementMei L Tan, Peng Shao, Anna M Friedhuber, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|January 29, 2011
Low intrinsic running capacity is associated with reduced skeletal muscle substrate oxidation and lower mitochondrial content in white skeletal muscleDonato A Rivas, Sarah J Lessard, Misato Saito, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The Journal of Pharmacy and Pharmacology|December 11, 2012
Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine modelMei Lin Tan, Anna M Friedhuber, Crispin R Dass
The Journal of Pharmacy and Pharmacology|September 12, 2014
Nucleotropic doxorubicin nanoparticles decrease cancer cell viability, destroy mitochondria, induce autophagy and enhance tumour necrosisAnna M Friedhuber, Vijay Chandolu, Somkamon Manchun, et al.
Journal of Microencapsulation|May 10, 2008
Biocompatible chitosan-DNAzyme nanoparticle exhibits enhanced biological activityCrispin R Dass, Anna M Friedhuber, Levon M Khachigian, et al.
Cancer Biology & Therapy|April 17, 2008
Downregulation of c-jun results in apoptosis-mediated anti-osteosarcoma activity in an orthotopic modelCrispin R Dass, Anna M Friedhuber, Levon M Khachigian, et al.
Biomaterials|October 20, 2009
The performance of doxorubicin encapsulated in chitosan-dextran sulphate microparticles in an osteosarcoma modelMei L Tan, Anna M Friedhuber, Dave E Dunstan, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 19, 2010
A nanoparticulate system that enhances the efficacy of the tumoricide Dz13 when administered proximal to the lesion siteMei Lin Tan, Dave E Dunstan, Anna M Friedhuber, et al.
The Journal of Pharmacy and Pharmacology|September 12, 2014
Cardiomyocyte apoptosis vs autophagy with prolonged doxorubicin treatment: comparison with osteosarcoma cellsOktay Tacar, Sivanjah Indumathy, Mei Lin Tan, et al.
Bone|April 28, 2019
Triple-threat activity of PEDF in bone tumors: Tumor inhibition, tissue preservation and cardioprotection against doxorubicinYongzhong Wei, Mina Elahy, Anna M Friedhuber, et al.
Biomaterials|June 21, 2014
The potential role of free chitosan in bone trauma and bone cancer managementMei L Tan, Peng Shao, Anna M Friedhuber, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|January 29, 2011
Low intrinsic running capacity is associated with reduced skeletal muscle substrate oxidation and lower mitochondrial content in white skeletal muscleDonato A Rivas, Sarah J Lessard, Misato Saito, et al.
Pageof 1